Le Lézard
Classified in: Health
Subjects: CHI, FDA

Leading Probiotic, GanedenBC30, Receives FDA GRAS for Infants


CLEVELAND, Jan. 18, 2017 /PRNewswire/ -- Ganeden continues its trend of being the first to receive regulatory approvals with the announcement that GanedenBC30® (Bacillus coagulans GBI-30, 6086) is FDA GRAS for infant formulas. Already known as the leading probiotic ingredient for functional foods and beverages, GanedenBC30 is now expanding its formulation opportunities into the new space. While the probiotic supplier's previous FDA GRAS certification covered products that could be fed to infants and children, the newest approval allows the strain to be the first and only spore-former to be used specifically in infant formulas.

An independent and critical evaluation was performed reviewing the safety of GanedenBC30 relating to usage in infant formulas. The evaluation was conducted by a panel of safety experts, including the Chair of the Department of Pediatrics at Massachusetts General Hospital and Harvard Professor, and overseen by AIBMR. Scientific research on Ganeden's strain was evaluated and the panel unanimously determined that GanedenBC30 is GRAS for use in infant formula. After receiving Self-affirmed GRAS in the Fall of 2016, the international ingredient supplier submitted a notification to the FDA for use in infant formula, which has now received a no objection letter.

"The safety and efficacy of the GanedenBC30 strain continues to be undoubtedly proven through solid science, leading to the receipt of numerous domestic and international certifications and approvals," said Mike Bush, president of Ganeden.  "There are few approvals more stringent than those pertaining to infants, and our certification in infant formula speaks highly to the quality and safety of our strain, and the solid foundation of research behind it."

Probiotics have become increasingly popular in infant products as awareness continues to rise around the importance of boosting beneficial bacteria from the start of life. Babies are born with sterile digestive tracts, and a variety of factors can affect the natural gut flora and the development of their digestive system.

"Whether a baby is bottle fed, delivered via C-section or has to be put on antibiotics all adversely affect their GI system," said Dr. David Keller, VP of scientific operations. "It is important to build up the good bacteria, and using a proven probiotic strain like GanedenBC30 can aid infants in this process."

GanedenBC30 was the first Bacillus strain to receive GRAS directly from the FDA for adult usage, and has already been formulated into more than 550 probiotic foods and beverages worldwide, including a variety of children's products. The ingredient supplier is now in discussions with leading companies in the infant category to discuss new probiotic developments.

For more information on Ganeden, including its probiotic ingredients and research, visit GandedenProbiotics.com.

About Ganeden:
Ganeden is at the forefront of probiotic research and product development with an extensive library of published studies and more than 130 patents for probiotic technologies in the food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30® (Bacillus coagulans GBI-30, 6086), its patented, FDA GRAS, non-GMO, highly stable probiotic ingredient.  Ganeden's newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com.

About GanedenBC30:
GanedenBC30® (Bacillus coagulans GBI-30, 6086), Ganeden's patented probiotic ingredient that can be found in more than 550 leading food, beverage, sports nutrition and companion animal products around the world. Unlike most other probiotic strains, GanedenBC30 is a spore-former which makes it highly stable and allows it to remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid.  The efficacy of GanedenBC30 is backed by over 20 published studies showing safety, digestive and immune support and GanedenBC30 has an exceptional safety record with FDA GRAS status from the United States FDA. It can be formulated into virtually any food, beverage or companion animal product that is baked, boiled, frozen or squeezed.... including all hot or refrigerated beverages!  For more information, please visit GanedenBC30.com.

 

SOURCE Ganeden


These press releases may also interest you

at 11:35
The Bone Health and Osteoporosis Foundation (BHOF) announced today its call for nominees for the newly created Robert F. Gagel, M.D. Community Leadership Award. The award's intent is to recognize healthcare professionals who are instrumental in...

at 11:33
Celebrating the 40th anniversary of The Glaucoma Foundation, writer, performer and producer David Letterman was front and center at TGF's April 18th Gala in New York City, where he received the Foundation's inaugural Chairman's Spotlight Award....

at 11:30
CancerIQ, a best-in-class cancer-focused precision health platform, today announced it is seeking health systems to participate in the newly launched, large-scale research effort that will document...

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 11:00
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive...



News published on and distributed by: